These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8503242)

  • 1. Minimal residual disease detected by the PCR in chronic myeloid leukemia. Comparison of cyclophosphamide-total body irradiation and busulphan-cyclophosphamide bone marrow transplantation conditioning.
    Stark RA; Richard P; Devergie A; Galibert F; Gluckman E
    Acta Haematol; 1993; 89(2):108-9. PubMed ID: 8503242
    [No Abstract]   [Full Text] [Related]  

  • 2. Busulfan/cyclophosphamide plus bone marrow transplantation is not sufficient to eradicate the malignant clone in juvenile chronic myelogenous leukemia.
    Urban C; Schwinger W; Slavc I; Schmid C; Gamillscheg A; Lackner H; Hauer C; Pakisch B
    Bone Marrow Transplant; 1990 May; 5(5):353-6. PubMed ID: 2190661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia.
    Clift RA; Radich J; Appelbaum FR; Martin P; Flowers ME; Deeg HJ; Storb R; Thomas ED
    Blood; 1999 Dec; 94(11):3960-2. PubMed ID: 10627126
    [No Abstract]   [Full Text] [Related]  

  • 4. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
    Demirer T; Buckner CD; Appelbaum FR; Lambert K; Bensinger WI; Clift R; Storb R; Slattery JT
    Bone Marrow Transplant; 1996 Mar; 17(3):341-6. PubMed ID: 8704684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
    Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
    Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful pregnancy following busulfan and cyclophosphamide conditioning and allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Matias K; Matias C; Teixeira H; Freire AD; Azevedo A
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):944-5. PubMed ID: 18640580
    [No Abstract]   [Full Text] [Related]  

  • 8. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
    Galimberti M; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Giardini C; Gaziev D; Erer B; Ripalti M; Rapa S
    Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of re-appearance of BCR-ABL-positive cells years after allogeneic bone marrow transplantation for chronic-phase chronic myelogenous leukemia in patients in hematological remission.
    Diekmann L; Beelen DW; Quabeck K; Becher R; Schulte Holthausen H; Bützler R; Schaefer UW; Opalka B
    Acta Haematol; 1994; 92(4):169-75. PubMed ID: 7701913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.
    Brodsky I; Biggs JC; Szer J; Crilley P; Atkinson K; Downs K; Dodds A; Concannon AJ; Avalos BR; Tutschka P
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):27-31; quiz 32. PubMed ID: 8342072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marrow transplantation following busulfan and cyclophosphamide for chronic myelogenous leukaemia in accelerated or blastic phase.
    Copelan EA; Grever MR; Kapoor N; Tutschka PJ
    Br J Haematol; 1989 Apr; 71(4):487-91. PubMed ID: 2653406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total body irradiation in acute myeloid leukemia and chronic myelogenous leukemia: influence of dose and dose-rate on leukemia relapse.
    Scarpati D; Frassoni F; Vitale V; Corvo R; Franzone P; Barra S; Guenzi M; Orsatti M
    Int J Radiat Oncol Biol Phys; 1989 Sep; 17(3):547-52. PubMed ID: 2674077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effectiveness of allogeneic bone marrow transplantation in patients with acute leukemia in complete remission and in patients with chronic myeloid leukemia during the chronic phase].
    Liubimova LS; Savchenko VG; Mendeleeva LP; Kliasova GA; Gribanova EO; Demidova IA; Gal'tseva IV; Kuz'mina LA; Momotiuk KS; Kuliev RG
    Ter Arkh; 1999; 71(7):27-32. PubMed ID: 10481864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of minimal residual leukemia after bone marrow transplantation in patients with chronic myeloid leukemia using the polymerase chain reaction].
    Matsue K; Nakamura K; Mizutani S
    Rinsho Ketsueki; 1990 May; 31(5):603-8. PubMed ID: 2395211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The assessment of therapeutic success in chronic myeloid leukemia].
    Griesshammer M; Hehlmann R; Heimpel H
    Dtsch Med Wochenschr; 1995 Apr; 120(17):620-5. PubMed ID: 7537652
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chronic myeloid leukemia. State of the art, May 1993].
    Hehlmann R
    Schweiz Med Wochenschr; 1994 Jan; 124(1-2):37-43. PubMed ID: 8296189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning.
    Lange T; Deininger M; Brand R; Hegenbart U; Al-Ali H; Krahl R; Poenisch W; Uharek L; Leiblein S; Gentilini C; Petersdorf E; Storb RF; Niederwieser D
    Leukemia; 2004 Sep; 18(9):1468-75. PubMed ID: 15241437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
    Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fertility after bone marrow transplantation following conditioning with cyclophosphamide and total body irradiation.
    Jacob A; Goodman A; Holmes J
    Bone Marrow Transplant; 1995 Mar; 15(3):483-4. PubMed ID: 7599577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.